☆ 4.7 Article

Thiopurine therapy in inflammatory bowel disease in the pandemic era: Safe or unsafe?

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Biochemistry & Molecular Biology

Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19

George Vere et al.

Summary: This review discusses potential therapeutic intervention points in COVID-19 treatment, including PLpro, USP18, TRIM25, CYLD, A20, and others, which may be effective in combating current and future vaccine-resistant variants of the virus.

BIOMOLECULES (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Use of thiopurines in inflammatory bowel disease: an update

Arshdeep Singh et al.

Summary: Inflammatory bowel disease (IBD) is now a global disease, with treatment mainly involving biologics and thiopurines, although their use is limited in developing countries. Thiopurines are critical for IBD patients in these regions, but face restrictions in usage.

INTESTINAL RESEARCH (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Management of inflammatory bowel disease in the COVID-19 era

Kyeong Ok Kim et al.

Summary: During the COVID-19 pandemic, patients with inflammatory bowel disease (IBD) do not seem to have an increased risk of contracting the virus. Current medications for IBD may even have potential therapeutic benefits against COVID-19 and should be continued, except for high-dose corticosteroids. Adherence to general recommendations and special treatment for COVID-19 patients are essential during this time.

INTESTINAL RESEARCH (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study

Lennard P. L. Gilissen et al.

Summary: The study investigated the severity of COVID-19 in patients with inflammatory bowel disease (IBD) one year after the SARS-CoV-2 outbreak, and found no significant association between IBD, immunosuppressants, and increased risk of severe COVID-19. However, the hospitalization rate in the IBD cohort was significantly higher than the regional level.

CLINICAL AND EXPERIMENTAL MEDICINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience

Vered Richter et al.

Summary: This study found that IBD patients do not have an increased risk of COVID-19, regardless of the severity of their disease or the type of treatment they receive. It is recommended that patients continue with effective IBD therapy, including biologics and steroids, to minimize disease activity.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Review Environmental Sciences

Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic

Rekha Khandia et al.

Summary: Since December 2019, SARS-CoV-2 has been rapidly evolving and mutating, leading to various variants with different levels of infectivity and lethality. The most recent variant of concern is Omicron (B.1.1.529), which has raised concerns about its ability to evade pre-existing immunity and overcome antibody-based therapies. Several theories have been proposed to explain the high number of mutations in Omicron. To successfully handle the ongoing pandemic, a multifaceted approach including rapid diagnosis, genome analysis, vaccination, and updated medical facilities is needed.

ENVIRONMENTAL RESEARCH (2022)

添加到收藏夹

Article Rheumatology

The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19

Martina Orlandi et al.

Summary: This study aimed to differentiate between COVID-19 pneumonia and SSc-ILD using CT features. Key findings included fibrosis inside focal ground-glass opacities in the upper lobes for SSc-ILD and consolidation in the lower lobes for COVID-19 pneumonia. A predictive score was developed with high sensitivity and specificity for COVID-19 diagnosis.

RHEUMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Multidimensional 3-Month Follow-Up of Severe COVID-19: Airways beyond the Parenchyma in Symptomatic Patients

Matteo Bonato et al.

Summary: SARS-CoV-2 may lead to pulmonary sequelae. A longitudinal study of severe COVID-19 survivors found that patients at three months from discharge showed functional impairment and radiological abnormalities, with respiratory symptoms related to airway sequelae.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Immunology

Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine

Moein Shirzad et al.

Summary: This paper reviews different treatment strategies against COVID-19 and provides a summary of traditional and newer methods in curing COVID-19.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Risks of Development of COVID-19 Among Patients With Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection

Millie D. Long et al.

Summary: This study examined the relationship between clinical risk factors and medication use in IBD patients and the development of COVID-19. The results showed that the use of immunosuppressive medications did not increase the risk of developing COVID-19.

CROHNS & COLITIS 360 (2022)

添加到收藏夹

Letter Gastroenterology & Hepatology

Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases

Erica J. Brenner et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research

Hiroshi Nakase et al.

Summary: It is crucial to accurately assess the risk of SARS-CoV-2 infection and COVID-19 severity in patients with IBD, as well as to manage IBD during the pandemic with input from COVID-19 cohorts and IBD experts. Key messages include: (1) no evidence that IBD itself increases the risk of SARS-CoV-2 infection, (2) prioritizing disease activity control, (3) no abrupt discontinuation of immunomodulatory or biologic therapy for stable IBD patients, and (4) careful monitoring of elderly patients and those on corticosteroid treatment during the COVID-19 pandemic.

DIGESTION (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules

Anke L. H. Nguyen et al.

Summary: In the management of inflammatory bowel disease, the role of thiopurines remains essential as steroid-sparing and maintenance agents. Despite safety concerns, the benefits of thiopurines outweigh risks in the majority of patients, especially when used in combination therapy with biologics after careful screening and monitoring. Further optimization of thiopurine dosing and awareness of the association with malignancies are crucial in individualized patient care.

DIGESTIVE DISEASES AND SCIENCES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource

Evangelos Stournaras et al.

Summary: Thiopurine monotherapy is effective for long-term treatment in UC but less effective in CD. Intolerance to thiopurines is associated with an increased risk of surgery in UC patients, with a modest impact on the need for surgery in CD patients.

GUT (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Effect of IBD medications on COVID-19 outcomes: results from an international registry

Ryan C. Ungaro et al.

Summary: Combination therapy and thiopurines may be associated with an increased risk of severe COVID-19, while no significant differences were observed when comparing classes of biologicals. These findings warrant confirmation in large population-based cohorts.

GUT (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid Spain

Ivan Guerra et al.

Summary: Infection with SARS-CoV-2 in patients with inflammatory bowel disease (IBD) is not rare, with most patients having a mild disease course. Immunotherapy is not associated with greater severity of COVID-19, and myalgias may be related to a milder clinical course.

INFLAMMATORY BOWEL DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases

Kristin E. Burke et al.

Summary: In a multi-institutional cohort of patients with IBD, the use of systemic immunosuppression was not associated with an increased risk of COVID-19, while obesity was identified as a risk factor for COVID-19.

INFLAMMATORY BOWEL DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study

Mohamed Attauabi et al.

Summary: Patients with immune-mediated inflammatory diseases, including IBD, were less susceptible to COVID-19 compared to patients without such diseases, and use of immunosuppressive therapies or disease activity of IBD did not affect the disease course of COVID-19.

JOURNAL OF CROHNS & COLITIS (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

A review on medical management of inflammatory bowel disease during the coronavirus disease 2019 pandemic

Harleen Chela et al.

Summary: The COVID-19 pandemic has raised concerns about the management of high-risk patients, including those with compromised immune systems, especially individuals with inflammatory bowel disease. Limited data and suggestions from medical societies aim to minimize the risk of infection in these patients during the ongoing pandemic.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Review Microbiology

Characteristics of SARS-CoV-2 and COVID-19

Ben Hu et al.

Summary: This review summarizes the research progress on SARS-CoV-2 and COVID-19, including virology characteristics, pathogenesis, and recent advances in treatment methods. Furthermore, it discusses in detail the potential wildlife hosts and zoonotic origin of this emerging virus.

NATURE REVIEWS MICROBIOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study

Cristina Bezzio et al.

Summary: This study found that IBD patients with higher risk factors, such as obesity, active disease, and comorbidities, are at greater risk of adverse COVID-19 outcomes. However, IBD medications do not appear to pose additional risks.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

COVID-19 in IBD: The experience of a single tertiary IBD center

Fernando Rizzello et al.

Summary: The study found a higher incidence of COVID-19 in patients with IBD, but biological therapy does not seem to be a risk factor for infection. Most patients delayed or stopped biological therapy during the pandemic, but a small percentage continued regular treatment.

DIGESTIVE AND LIVER DISEASE (2021)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

COVID-19 and IBD drugs: should we change anything at the moment?

Charlie W. Lees et al.

GUT (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Severe COVID-19 in inflammatory bowel disease patients in a population-based setting

Rob H. Creemers et al.

Summary: A study in the heavily impacted South-Limburg region in the Netherlands found a significantly higher hospitalization rate for COVID-19 in patients with inflammatory bowel disease (IBD), but the severe course of the disease was similar to non-IBD hospitalized patients.

PLOS ONE (2021)

添加到收藏夹

Review Chemistry, Physical

Diagnostics for SARS-CoV-2 infections

Bhavesh D. Kevadiya et al.

Summary: The outbreak of SARS-CoV-2 causing COVID-19 has led to diverse and severe symptoms, making accurate diagnosis a key challenge. Rapid diagnosis and treatment measures are crucial in controlling the spread of the virus. The development of diagnostic tools, including nanomaterial-based ones, is essential in the fight against the pandemic.

NATURE MATERIALS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

Jerzy Osipiuk et al.

Summary: The study focused on papain-like protease (PLpro) as a potential target for antivirals against SARS-CoV-2, identifying inhibitors and their interactions with the enzyme. The findings demonstrate the potential for developing high-affinity inhibitors through structure-based drug design efforts targeting PLpro.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases

Keiichi Tominaga et al.

Summary: Thiopurines are medications used to treat inflammatory bowel diseases, particularly ulcerative colitis, with the potential to alleviate symptoms and maintain long-term remission. Careful monitoring is needed for adverse events associated with long-term use, while these drugs also play a critical role in controlling immunogenicity and predicting serious adverse events. However, the consequences of thiopurine withdrawal remain uncertain and further research is required to address this clinical question.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro

Caleb D. Swaim et al.

Summary: The study suggests that 6-Thioguanine (6-TG) can effectively inhibit SARS-CoV-2 replication, as well as inhibit PLpro-catalyzed polyprotein cleavage and de-ISGylation.

ISCIENCE (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician

Julio Maria Fonseca Chebli et al.

Summary: Managing inflammatory bowel disease (IBD) during the COVID-19 pandemic presents challenges for clinicians and patients, especially regarding the use of biologics and immunosuppressive agents, and the impact of SARS-CoV-2 infection on patients.

WORLD JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey

Natalia Sousa Freitas Queiroz et al.

Summary: The study reveals a distinct geographical distribution of IBD patients at highest risk for COVID-19 complications in different states of Brazil, potentially due to varying socioeconomic, educational, and healthcare factors. There was no association found between high risk of IBD and COVID-related mortality rates.

WORLD JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes

Irwin Jungreis et al.

Summary: Despite the clinical importance, the SARS-CoV-2 gene set remains unresolved, hindering dissection of COVID-19 biology. By comparing 44 Sarbecovirus genomes, a high-confidence protein-coding gene set is provided, characterizing protein-level and nucleotide-level evolutionary constraints, and prioritizing functional mutations from the ongoing COVID-19 pandemic.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis

Qiang Miao et al.

Summary: The study confirmed that NUDT15 variants are potential independent risk predictors for AZA-induced leukopenia and neutropenia, while TPMT*3C and ITPA variants are not significantly associated with myelosuppression. Additionally, BMI may be a crucial non-genetic factor that affects the concentration of AZA metabolites and myelosuppression.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Pediatrics

Children With Inflammatory Bowel Disease in the COVID-19 Main Endemic Focus: The Lombardy Experience

Naire Sansotta et al.

Summary: During the COVID-19 pandemic in Lombardy, most children with IBD only experienced mild symptoms without requiring hospitalization or treatment modifications. After the lockdown, there were new IBD diagnoses and relapses in some known IBD children, but no significant difference was found compared to the previous year.

FRONTIERS IN PEDIATRICS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study

Antoine Meyer et al.

Summary: The study compared the risk of severe COVID-19 among patients with inflammatory bowel disease (IBD) on different medications and found that immunomodulators and biologics do not appear to increase the severity of COVID-19 infection in this population.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India

Narinder Grover et al.

Summary: The study found that NUDT15 polymorphism was more common than TPMT polymorphism in South Asian IBD patients, and was associated with thiopurine-induced leukopenia. However, the tested polymorphisms only accounted for 24.2% of the risk of thiopurine-induced leukopenia.

BMC GASTROENTEROLOGY (2021)

添加到收藏夹

Article

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications

Laura E Targownik et al.

Journal of the Canadian Association of Gastroenterology (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry

Natalia S. F. Queiroz et al.

Summary: In Latin America, IBD patients diagnosed with COVID-19 have similar outcomes to global data, with risk factors for severe COVID-19 being similar to previous reports.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Article Neurosciences

NK Cell Subpopulations and Receptor Expression in Recovering SARS-CoV-2 Infection

Marina Saresella et al.

Summary: The study found that severe cases of COVID-19 were characterized by an expansion of NK cells with lower cytolytic activity and an increased expression of the 2DL1 inhibitory receptor, while patients recovering from mild or moderate infection showed an increase in NK cells expressing the ILT2 inhibitory receptor. These results suggest that alterations in NK cell activity may play a role in the severity of COVID-19 infection.

MOLECULAR NEUROBIOLOGY (2021)

添加到收藏夹

Article Geriatrics & Gerontology

Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease

Margalida Calafat et al.

Summary: This study investigated the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease, and found that the incidence of COVID-19 was similar among elderly IBD patients regardless of the use of immunosuppressants, compared to the background population.

AGING CLINICAL AND EXPERIMENTAL RESEARCH (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD

Christian Philipp Selinger et al.

Summary: The impact of COVID-19 on pregnant inflammatory bowel disease (IBD) patients and the adjustments made to antenatal care during the pandemic did not negatively affect patient care. Despite high levels of immunosuppression, only one suspected COVID-19 infection occurred among the pregnant women with IBD. Adverse pregnancy outcomes were infrequent.

BMJ OPEN GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Care of inflammatory bowel disease patients during coronavirus disease-19 pandemic using digital health-care technology

Uday C. Ghoshal et al.

Summary: Teleconsultation is a feasible and acceptable alternative for IBD patients, who had similar rates of COVID-19 infection as non-IBD controls during the pandemic, likely due to their disease awareness and prevention practices. Quality of life scores (except for environmental domains) and psychological issues were quite comparable or even better during the COVID-19 pandemic than earlier.

JGH OPEN (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain

Ivan Guerra et al.

Summary: SARS-CoV-2 infection in patients with inflammatory bowel disease (IBD) is not rare. Therapy for IBD is not related to COVID-19 severity, and COVID-19 does not appear to induce IBD flare-ups.

INFLAMMATORY BOWEL DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Roujian Lu et al.

LANCET (2020)

添加到收藏夹

Article Microbiology

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Alexander E. Gorbalenya et al.

NATURE MICROBIOLOGY (2020)

添加到收藏夹

Editorial Material Immunology

COVID-19: a new challenge for human beings

Penghui Yang et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

添加到收藏夹

Letter Gastroenterology & Hepatology

Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts

Mariangela Allocca et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California

John Gubatan et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain)

Iago Rodriguez-Lago et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy

Lorenzo Norsa et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Erica J. Brenner et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary

David T. Rubin et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Impact of Anti-Tumor Necrosis Factor and Thiopurine Medications on the Development of COVID-19 in Patients With Inflammatory Bowel Disease: A Nationwide Veterans Administration Cohort Study

Nabeel Khan et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

Cristina Bezzio et al.

GUT (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Nicholas A. Kennedy et al.

GUT (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature

Melissa H. Rosen et al.

INFLAMMATORY BOWEL DISEASES (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce

F. Magro et al.

JOURNAL OF CROHNS & COLITIS (2020)

添加到收藏夹

Article Infectious Diseases

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

Lucy van Dorp et al.

INFECTION GENETICS AND EVOLUTION (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Inflammatory Bowel Disease - Non-biological treatment

Fernando Magro et al.

PHARMACOLOGICAL RESEARCH (2020)

添加到收藏夹

Article Virology

Characterization of accessory genes in coronavirus genomes

Christian Jean Michel et al.

VIROLOGY JOURNAL (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Immunosuppressive Drugs and COVID-19: A Review

Tessa S. Schoot et al.

FRONTIERS IN PHARMACOLOGY (2020)

添加到收藏夹

Review Medicine, General & Internal

Gastrointestinal insights during the COVID-19 epidemic

Kai Nie et al.

WORLD JOURNAL OF CLINICAL CASES (2020)

添加到收藏夹

Article Immunology

Immunotherapeutic approaches to curtail COVID-19

Hajar Owji et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data

Fabio Salvatore Macaluso et al.

DIGESTIVE AND LIVER DISEASE (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID-19 pandemic

Khoon Lin Ling et al.

JGH OPEN (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review

Jean-Frederic Colombel et al.

JOURNAL OF CROHNS & COLITIS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease

Shan-Shan Gong et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Usefulness of Thiopurine Monotherapy for Crohn's Disease in the Era of Biologics: A Long-Term Single-Center Experience

Cristina Suarez Ferrer et al.

DIGESTIVE DISEASES AND SCIENCES (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring

Sheng Zhang Lim et al.

FRONTIERS IN PHARMACOLOGY (2018)

添加到收藏夹

Review Immunology

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Prashanth Rawla et al.

JOURNAL OF INFLAMMATION RESEARCH (2018)

添加到收藏夹

Review Immunology

Optimising use of thiopurines in inflammatory bowel disease

Robin J. Dart et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)

添加到收藏夹

Review Gastroenterology & Hepatology

Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease

Raja Atreya et al.

VISCERAL MEDICINE (2017)

添加到收藏夹

Review Gastroenterology & Hepatology

Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective

Jordan E. Axelrad et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2016)

添加到收藏夹

Review Pharmacology & Pharmacy

The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds

Yahira M. Baez-Santos et al.

ANTIVIRAL RESEARCH (2015)

添加到收藏夹

Article Pharmacology & Pharmacy

Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus

Kai-Wen Cheng et al.

ANTIVIRAL RESEARCH (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical predictors of thiopurine-related adverse events in Crohn's disease

Gordon W. Moran et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2015)

添加到收藏夹

Review Pharmacology & Pharmacy

Optimizing the use of thiopurines in inflammatory bowel disease

Rishi M. Goel et al.

THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2015)

添加到收藏夹

Article Pharmacology & Pharmacy

Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features

Jian Lei et al.

ANTIVIRAL RESEARCH (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

Remo Panaccione et al.

GASTROENTEROLOGY (2014)

添加到收藏夹

Review Gastroenterology & Hepatology

Opportunistic Infections Due to Inflammatory Bowel Disease Therapy

Maneesh Dave et al.

INFLAMMATORY BOWEL DISEASES (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Immunosuppressive therapies for inflammatory bowel disease

Talia Zenlea et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.

Jean Frederic Colombel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Gastroenterology & Hepatology

Azathioprine Is Superior to Budesonide in Achieving and Maintaining Mucosal Healing and Histologic Remission in Steroid-dependent Crohn's Disease

Gerassimos J. Mantzaris et al.

INFLAMMATORY BOWEL DISEASES (2009)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients

J. P. Gisbert et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)

添加到收藏夹

Article Pharmacology & Pharmacy

Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus

Chi-Yuan Chou et al.

BIOCHEMICAL PHARMACOLOGY (2008)

添加到收藏夹

Article Virology

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

N Barretto et al.

JOURNAL OF VIROLOGY (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.